drugset / Trial / NCT05954091
OH2 Administered by Intratumoral Injection
NaSingle-groupOpen-labelTreatment
Summary
This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of OH2 in patients with locally advanced/metastatic solid tumors.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2027-07-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OH2 | Other / unclassified | 1e+06 unknown | Other |
| Subject | OH2 | Other / unclassified | 5e+06 unknown | Other |
| Subject | OH2 | Other / unclassified | 1e+07 unknown | Other |